Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Express Scripts
Moodys
Medtronic

Last Updated: May 19, 2022

XGEVA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Tradename: XGEVA
Patents:0
Applicants:1
BLAs:1
Pharmacology for XGEVA
Mechanism of ActionRANK Ligand Blocking Activity
Established Pharmacologic ClassRANK Ligand Inhibitor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XGEVA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XGEVA Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2016-12-23 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2017-04-16 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2021-06-26 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2016-12-23 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2016-12-23 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2017-04-16 Company disclosures
Amgen, Inc. XGEVA denosumab Injection 125320 See Plans and Pricing 2021-06-26 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for XGEVA Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for XGEVA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300464 Netherlands See Plans and Pricing PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
SPC/GB10/043 United Kingdom See Plans and Pricing PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
300465 Netherlands See Plans and Pricing PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
44/2010 Austria See Plans and Pricing PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
2010/035 Ireland See Plans and Pricing PRODUCT NAME: DENOSUMAB (PROLIA ); NAT REGISTRATION NO/DATE: EU/1/10/618/001 20100526; FIRST REGISTRATION NO/DATE: EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 26/05/2010 IRELAND EU/1/10/618/001 26/05/2010 IRELAND EU/1/10/618/002 26/05/2010 IRELAND EU/1/10/618/003 26/05/2010 IRELAND EU/1/10/618/004 20100526
91757 Luxembourg See Plans and Pricing PRODUCT NAME: DENOSUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (PROLIA ); AUTHORISATION NUMBER AND DATE: EU/1/10/618/001-004 20100528
300467 Netherlands See Plans and Pricing PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100528
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Moodys
Baxter
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.